Mayinglong Pharmaceutical Group Crescita futura

Future criteri di controllo 2/6

Mayinglong Pharmaceutical Group prevede che gli utili e i ricavi cresceranno rispettivamente di 18.9% e 14.4% all'anno. Si prevede che l'EPS crescerà di 18.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14.7% in 3 anni.

Informazioni chiave

18.9%

Tasso di crescita degli utili

18.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.9%
Tasso di crescita dei ricavi	14.4%
Rendimento futuro del capitale proprio	14.7%
Copertura analitica	Low
Ultimo aggiornamento	19 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Oct 01

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Aug 19

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 24

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Jun 19

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 07

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mar 22

Previsioni di crescita degli utili e dei ricavi

SHSE:600993 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	4,840	767	672	748	2
12/31/2025	4,276	687	501	628	2
12/31/2024	3,727	573	381	437	2
9/30/2024	3,482	482	543	845	N/A
6/30/2024	3,424	474	602	864	N/A
3/31/2024	3,259	453	497	754	N/A
12/31/2023	3,137	443	356	604	N/A
9/30/2023	3,194	481	18	162	N/A
6/30/2023	3,245	488	270	396	N/A
3/31/2023	3,416	529	286	388	N/A
12/31/2022	3,532	479	267	342	N/A
9/30/2022	3,640	513	600	665	N/A
6/30/2022	3,644	482	547	607	N/A
3/31/2022	3,473	485	522	580	N/A
12/31/2021	3,385	465	532	597	N/A
9/30/2021	3,587	457	81	144	N/A
6/30/2021	3,479	439	-13	55	N/A
3/31/2021	3,317	427	92	158	N/A
12/31/2020	2,792	419	238	283	N/A
9/30/2020	2,518	396	651	687	N/A
6/30/2020	2,411	378	543	582	N/A
3/31/2020	2,431	336	425	468	N/A
12/31/2019	2,705	360	445	492	N/A
9/30/2019	2,528	349	190	233	N/A
6/30/2019	2,400	290	344	374	N/A
3/31/2019	2,311	241	355	385	N/A
12/31/2018	2,198	176	283	308	N/A
9/30/2018	2,152	205	289	321	N/A
6/30/2018	2,041	248	N/A	185	N/A
3/31/2018	1,861	302	N/A	252	N/A
12/31/2017	1,751	320	N/A	356	N/A
9/30/2017	1,884	279	N/A	314	N/A
6/30/2017	1,937	266	N/A	377	N/A
3/31/2017	2,013	257	N/A	291	N/A
12/31/2016	2,103	250	N/A	240	N/A
9/30/2016	1,924	245	N/A	271	N/A
6/30/2016	1,893	238	N/A	117	N/A
3/31/2016	1,833	230	N/A	211	N/A
12/31/2015	1,784	223	N/A	183	N/A
9/30/2015	1,739	207	N/A	142	N/A
6/30/2015	1,657	215	N/A	197	N/A
3/31/2015	1,642	203	N/A	96	N/A
12/31/2014	1,621	201	N/A	112	N/A
9/30/2014	1,607	205	N/A	119	N/A
6/30/2014	1,623	199	N/A	90	N/A
3/31/2014	1,605	188	N/A	111	N/A
12/31/2013	1,602	186	N/A	130	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600993 ( 18.9% all'anno) è superiore al tasso di risparmio ( 2.8% ).

Guadagni vs Mercato: Si prevede che gli utili di 600993 ( 18.9% all'anno) cresceranno più lentamente rispetto al mercato CN ( 26.3% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600993 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 600993 ( 14.4% all'anno) crescerà più rapidamente del mercato CN ( 13.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600993 ( 14.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600993 sarà basso tra 3 anni ( 14.7 %).

Mayinglong Pharmaceutical Group Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 3Q 2023)

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2023)

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Dividend increased to CN¥0.40

Now 23% overvalued after recent price rise

Now 15% overvalued after recent price rise

Now 18% overvalued after recent price rise

Now 21% overvalued after recent price rise

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Mayinglong Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 18, 2024

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥1.11 in FY 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mayinglong Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.34 in 3Q 2022)

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.31 in 2Q 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Full year 2022 earnings released: EPS: CN¥1.11 (vs CN¥1.08 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2021)

Now 20% undervalued

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.32 in 2Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.22 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.30 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.25 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.97 (vs CN¥0.84 in FY 2019)

Mayinglong Pharmaceutical Group Co., LTD. to Report Fiscal Year 2020 Results on Mar 26, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥19.37

Investor sentiment improved over the past week

New 90-day high: CN¥22.46

New 90-day low: CN¥20.34

Third quarter earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day low: CN¥20.92

Earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report First Half, 2020 Results on Aug 22, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita